8 stories mentioning TYO:4507Updated 17d ago
Every FINWIRES story that references TYO:4507, newest first.
Shionogi (TYO:4507) has an average rating of overweight and mean price target of 3,388.46 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Shionogi & Co. (TYO:4507) board approved the disposal of 201,300 treasury shares totaling up to 567.6 million yen under its restricted stock compensation plan.The shares were allocated to two directors, excluding audit & supervisory committee member directors and outside directors; 15 corporate officers; and 60 vice presidents, according to a Wednesday filing on the Tokyo Stock Exchange.The disposal will be completed on July 23.
Shionogi & Co. (TYO:4507) said it secured supplemental approval for the pediatric dosage and administration of its Xocova drug for the treatment of COVID-19 in Japan, according to a Friday release.The Japan-based pharmaceutical company said that the approval expands the drug's usage among pediatric patients aged 6 to under 12 years who weigh at least 20 kilograms.The approval also covers a new 25-milligram tablet and follows results from a Phase 3 clinical trial involving 117 children in Japan.
Shionogi & Co (TYO:4507) and F2G reported positive late-stage trial results for their antifungal pill olorofim, tested in patients with invasive aspergillosis who cannot use standard azole treatments.The trial found that olorofim worked just as well as the current intravenous treatment, with similar survival rates at 42 days-about 76% of patients in both groups were still alive, according to a Tokyo bourse filing on Thursday.Importantly, the new pill caused far fewer side effects, especially kidney-related problems, which are a major concern with existing therapies.The drug already holds FDA Breakthrough status, and the companies now plan to file for regulatory approval in the US, Europe, and Asia.If approved, this would be the first new class of antifungal medicine in over 20 years, offering a much-needed oral alternative for vulnerable patients with weak immune systems.
Shionogi & Co (TYO:4507) has an average rating of overweight and mean price target of 3,392.31 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
The US Food and Drug Administration approved Shionogi & Co's (TYO:4507) Xocova or ensitrelvir as the first and only oral antiviral for post-exposure prophylaxis of COVID-19 in individuals aged 12 and older, according to a Tokyo bourse filing on Monday.The approval, which came ahead of the June 16 Prescription Drug User Fee Act action date, was supported by Phase 3 Scorpio-PEP trial results, which showed a 67% reduction in symptomatic COVID-19 risk following exposure compared to placebo.The treatment was generally well tolerated, with adverse event rates similar to placebo, and no reports of altered taste attributed to the drug.
Shionogi & Co's (TYO:4507) oral antiviral ensitrelvir significantly reduced the risk of COVID-19 infection among household contacts of infected patients in a phase 3 post-exposure prophylaxis trial, according to study results published Wednesday.The randomized, double-blind, placebo-controlled study enrolled more than 2,000 participants across Japan, assigning them to receive either ensitrelvir or placebo within 72 hours of symptom onset in an index case. By day 10, COVID-19 occurred in 2.9% of those receiving ensitrelvir versus 9.0% in the placebo group, corresponding to a risk reduction of about 67%.The safety profile was broadly comparable between the two groups, with similar rates of adverse events and no COVID-19-related hospitalisations or deaths reported during the trial.Ensitrelvir is already approved in Japan for the treatment of mild-to-moderate COVID-19, and the company said the findings support its potential use in preventing infection following household exposure.
Shionogi & Co (TYO:4507) will absorb its wholly owned subsidiary Torii Pharmaceutical through an absorption-type merger effective April 1, 2027, as it moves to strengthen integration and decision-making, according to a Monday filing on the Tokyo Stock Exchange.The companies signed the merger agreement on April 27 following board approval the same day.Shionogi will remain the surviving entity, while Torii Pharmaceutical will be dissolved, with no new shares or cash consideration issued as part of the transaction.The company said the merger will deepen collaboration and enhance synergies, particularly in therapeutic areas such as allergy and dermatology.
